Business
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This p
About this update from Scisparc Ltd.
[{"type":"image","alt":"SciSparc Ltd","displaySize":"","headline":null,"caption":"SciSparc Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":296,"height":296,"url":"https://media.zenfs.com/en/globenewswire.com/be600651bf31c0eac5b1f38ffceddbae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MrHl.FxBjx0vaFl08ACRrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/be600651bf31c0eac5b1f38ffceddbae","width":296,"height":296}},"lazy":false},{"type":"text","content":"TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This patent covers methods and formulations designed to potentiate the therapeutic effects of opioids while significantly reducing associated side effects, such as tolerance, dependence, and gastrointestinal issues.","length":719,"tagName":"p"},{"type":"text","content":"This patent grant in Israel joins previously granted patents for the same technology in Europe, Japan, Australia, and Canada, further strengthening the global intellectual property protection of Neurothera’s proprietary opioid-based platform.","length":242,"tagName":"p"},{"type":"text","content":"The patented technology leverages N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms that amplify pain-relieving efficacy at lower doses. This patent family is based on a pre-clinical study conducted to evaluate the nociceptive effect of PEA when combined with opiates such as oxycodone, in well-established, regulatory compliance, pre-clinical models.","length":418,"tagName":"p"},{"type":"text","content":"In this study, researchers evaluated the pain relief potential of Neurothera’s proprietary drug combination of oxycodone and PEA versus standalone oxycodone in numerous concentrations.","length":184,"tagName":"p"},{"type":"text","content":"Results showed that while oxycodone treatment led to marked alterat...